SEC Form 4 · accession 0000899243-19-007350
XERIS PHARMACEUTICALS INC · XERS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Paul R Edick
Officer — See Remarks · Director
Period of report
Mar 11, 2019
Accepted (ET)
Mar 12, 2019 · 7:15 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001346302
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 11, 2019 | P | 30,000 | $9.1195 | A | 155,000 | D | |
| Common StockF2 | holding | — | — | — | 13,430 | I | By: Paul R. Edick 2008 Revocable Trust u/d/t dated 6/25/2018 |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.98 to $9.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
- F2The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Remarks
Chairman, President & Chief Executive Officer